Last reviewed · How we verify
GFH925
At a glance
| Generic name | GFH925 |
|---|---|
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations (PHASE1, PHASE2)
- A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation (PHASE1, PHASE2)
- Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (PHASE1)
- A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GFH925 CI brief — competitive landscape report
- GFH925 updates RSS · CI watch RSS
- Genfleet Therapeutics (Shanghai) Inc. portfolio CI